Biogen Bolsters Rare Disease Portfolio, Agrees To Buy Reata Pharmaceuticals With Enterprise Value Of $7.3B
Benzinga
JULY 28, 2023
per share in cash, reflecting an enterprise value of approximately $7.3 Biogen Inc (NASDAQ: BIIB ) has agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA ) for $172.50 Reata's FDA-approved Skyclarys (omaveloxolone) is the first and only approved treatment for Friedreich's ataxia (FA) in the U.S.,
Let's personalize your content